The antimalarial compound ELQ-400 is an unusual inhibitor of the bc1 complex, targeting both Qo and Qi sites

FEBS Lett. 2018 Apr;592(8):1346-1356. doi: 10.1002/1873-3468.13035. Epub 2018 Mar 26.

Abstract

Inhibitors of the mitochondrial respiratory chain cytochrome bc1 complex, such as the antimalarial atovaquone and ELQ-300, and many well-studied compounds, are classified as either Qo or Qi site inhibitors based on their site of action. Here, we investigated the site of action of ELQ-400 that showed an unusual behaviour, being effective against parasites resistant to the Qo site inhibitor atovaquone or to the Qi site inhibitor ELQ-300. Analysis of yeast mutants and comparison with atovaquone and other ELQs strongly suggest that ELQ-400 targets both Qo and Qi sites. Dual site inhibition would be particularly efficient as it would lower the risk of acquired resistance. However, such compounds are seldom found, which could be explained by structural and mechanistic differences between the sites.

Keywords: Qo and Qi site inhibitors; complex III; respiratory chain.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antimalarials / chemistry*
  • Electron Transport Complex III* / antagonists & inhibitors
  • Electron Transport Complex III* / chemistry
  • Enzyme Inhibitors / chemistry*
  • Molecular Docking Simulation*
  • Phenyl Ethers / chemistry*
  • Quinolones / chemistry*
  • Saccharomyces cerevisiae / enzymology*
  • Saccharomyces cerevisiae Proteins* / antagonists & inhibitors
  • Saccharomyces cerevisiae Proteins* / chemistry

Substances

  • Antimalarials
  • ELQ-400
  • Enzyme Inhibitors
  • Phenyl Ethers
  • Quinolones
  • Saccharomyces cerevisiae Proteins
  • Electron Transport Complex III

Associated data

  • PDB/4D6T
  • PDB/2A06